IMI has now launched its 11th Call for proposals with the following topics:
- Applied public-private research enabling osteoarthritis clinical headway
- European platform for proof of concept for prevention in Alzheimer’s disease
- Blood-based biomarker assays for personalised tumour therapy: value of latest circulating biomarkers
- Zoonoses anticipation and preparedness initiative
- Generation of research tools to translate genomic discoveries into drug discovery projects
- EcoRiskPrediction
Topics under the New Drugs for Bad Bugs (ND4BB) programme on antimicrobial resistance:
- Epidemiology research and development of novel systemic antibacterial molecules against healthcare-associated infections due to Gram-negative pathogens
- Subtopic: Epidemiology research and clinical development of a novel bispecific IgG antibody, Bis4αPA, for the prevention of serious Pseudomonas aeruginosa disease
- Subtopic: Clinical development of a novel resistance-breaking beta-lactam antibiotic, AIC499, in combination with a beta-lactamase inhibitor (BLI) against severe bacterial infections due to Gram-negative pathogens
- Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-CF bronchiectasis (BE)
Deadline for submitting Expressions of Interest (EoIs)
8 April 2014